- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07657208
Effects of Snoezelen Multisensory Therapy on Older Adults With Dementia (SMT)
Randomized Controlled Trial on the Effects of Snoezelen Multisensory Therapy on Behavioral, Psychological, and Physiological Symptoms in Older Adults With Dementia
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Dementia is a growing public health concern, with high rates of behavioral and psychological symptoms (BPSD), such as depression, agitation, and anxiety. Non-pharmacological therapies like Snoezelen Multisensory Therapy (SMT) are increasingly explored as safe and effective alternatives or complements to standard therapy (ST).
This randomized controlled clinical trial will evaluate the acute and chronic effects of SMT in 60 patients with dementia at the Center for Older Adults Lucija, Slovenia. Participants will be stratified by medication use and cognitive status and randomly assigned to either an experimental group receiving SMT + ST, or a control group receiving ST alone. SMT consists of 30-minute sessions in a multisensory room equipped according to Snoezelen® guidelines. Sessions will be personalized and monitored, including physiological measurements before and after therapy.
Primary outcomes will include changes in BPSD measured by the Cornell Scale for Depression in Dementia (CSDD), the Hospital Anxiety and Depression Scale (HADS), and the Cohen-Mansfield Agitation Inventory (CMAI). Physiological indicators such as heart rate (HR), heart rate variability (HRV), oxygen saturation (SpO2), skin conductance, and salivary cortisol will be collected before and after the 1st and 36th sessions. Medication use (PRN) will be tracked every two weeks.
The study includes translation and validation of BPSD assessment tools into Slovenian. Results are expected to contribute valuable data to the field of dementia care and support broader implementation of SMT in geriatric settings. This study was registered retrospectively on ClinicalTrials.gov after study completion.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Portorož, Slovenien, 6320
- Center for Older Adults Lucija
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
Age 65 years or older
Diagnosed dementia (any subtype)
Montreal Cognitive Assessment (MoCA) score between 10-25
Katz Performance Status Score (KPSS) between 10-24
Behavioral and psychological symptoms of dementia (BPSD), indicated by at least one of the following:
Cornell Scale for Depression in Dementia (CSDD) score >10
Hospital Anxiety and Depression Scale (HADS) score >8
Cohen-Mansfield Agitation Inventory (CMAI) showing moderate or severe symptoms
Ability to follow basic instructions and communicate needs
Written informed consent obtained from the participant or their legal representative
Exclusion Criteria:
- Acute psychiatric illness or unstable somatic condition
Severe visual or hearing impairments
Inability to communicate in Slovenian
Concurrent participation in psychotherapy or physiotherapy
Diagnosis of epilepsy
Changes to psychiatric medication within 4 weeks prior to study start
Any other condition that, in the opinion of the research team, would interfere with participation or data collectio
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: SMT + Standard Therapy
Participants in this group will receive standard therapy routinely provided at the care center in addition to Snoezelen Multisensory Therapy (SMT).
SMT will be delivered individually in a Snoezelen-designed multisensory room for 30 minutes, three times per week, over a 12-week period.
Sessions will be tailored to each participant's sensory profile and preferences.
|
A non-pharmacological, individualized sensory stimulation therapy delivered in a Snoezelen-designed multisensory environment.
Sessions include visual, auditory, tactile, and olfactory stimuli tailored to the participant's sensory profile and preferences.
The intervention is delivered individually for 30 minutes, three times per week, over a 12-week period and is intended to reduce behavioral and psychological symptoms of dementia and improve well-being.
Andre navne:
Standard therapy refers to routine care provided in the residential care setting and includes cognitive stimulation activities, group social interactions, occupational therapy, physical therapy, creative activities (e.g., art and music sessions), reminiscence therapy, and relaxation practices.
These interventions are delivered by trained staff as part of the regular care program.
No Snoezelen Multisensory Therapy or other multisensory stimulation interventions are provided as part of standard therapy.
Andre navne:
|
|
Aktiv komparator: Standard Therapy Only
Participants in this group will receive standard therapy routinely provided at the care center, including cognitive stimulation activities (e.g., memory games, orientation exercises, attention and problem-solving tasks), group social interactions, occupational therapy, physical therapy, creative activities (e.g., art and music sessions), reminiscence therapy, and relaxation practices.
No Snoezelen Multisensory Therapy (SMT) will be provided.
|
Standard therapy refers to routine care provided in the residential care setting and includes cognitive stimulation activities, group social interactions, occupational therapy, physical therapy, creative activities (e.g., art and music sessions), reminiscence therapy, and relaxation practices.
These interventions are delivered by trained staff as part of the regular care program.
No Snoezelen Multisensory Therapy or other multisensory stimulation interventions are provided as part of standard therapy.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in agitation level as measured by Cohen-Mansfield Agitation Inventory (CMAI)
Tidsramme: Baseline, Week 2, Week 4, Week 6, Week 8, Week 10, and Week 12
|
The Cohen-Mansfield Agitation Inventory (CMAI) is used to measure the frequency of agitated behaviors in elderly participants with dementia.
Scores range from 29 to 203, with higher scores indicating more frequent agitation.
|
Baseline, Week 2, Week 4, Week 6, Week 8, Week 10, and Week 12
|
|
Change in depressive symptoms as measured by Cornell Scale for Depression in Dementia (CSDD)
Tidsramme: Baseline, Week 2, Week 4, Week 6, Week 8, Week 10, and Week 12
|
The CSDD assesses signs of depression in individuals with dementia.
Scores range from 0 to 38, with higher scores indicating more severe depression.
|
Baseline, Week 2, Week 4, Week 6, Week 8, Week 10, and Week 12
|
|
Change in anxiety level (HADS-Anxiety Subscale)
Tidsramme: Baseline, Week 2, Week 4, Week 6, Week 8, Week 10, and Week 12
|
HADS-A is a validated subscale that measures anxiety in older adults.
Scores range from 0 to 21, with higher values indicating greater anxiety.
|
Baseline, Week 2, Week 4, Week 6, Week 8, Week 10, and Week 12
|
|
Change in heart rate
Tidsramme: Immediately before and immediately after Session 1 (Baseline), and immediately before and immediately after Session 36 (Week 12)
|
Heart rate is measured using wearable physiological sensors as an indicator of autonomic arousal and physiological response.
|
Immediately before and immediately after Session 1 (Baseline), and immediately before and immediately after Session 36 (Week 12)
|
|
Change in subjective well-being using a self-reported analog scale
Tidsramme: Immediately before and immediately after each SMT session, three times per week for 12 weeks (36 sessions total)
|
Participants report their mood, comfort, and overall well-being on a self-reported visual analog scale ranging from 0 to 5 before and after each SMT session.
|
Immediately before and immediately after each SMT session, three times per week for 12 weeks (36 sessions total)
|
|
Change in heart rate variability (HRV)
Tidsramme: Immediately before and immediately after Session 1 (Baseline), and immediately before and immediately after Session 36 (Week 12)
|
Heart rate variability (HRV) is measured using wearable physiological sensors as an indicator of autonomic nervous system regulation and physiological response to therapy.
|
Immediately before and immediately after Session 1 (Baseline), and immediately before and immediately after Session 36 (Week 12)
|
|
Change in skin conductance
Tidsramme: Immediately before and immediately after Session 1 (Baseline), and immediately before and immediately after Session 36 (Week 12)
|
Skin conductance is measured using wearable physiological sensors as an indicator of autonomic arousal and stress response
|
Immediately before and immediately after Session 1 (Baseline), and immediately before and immediately after Session 36 (Week 12)
|
|
Change in oxygen saturation (SpO₂)
Tidsramme: Immediately before and immediately after Session 1 (Baseline), and immediately before and immediately after Session 36 (Week 12)
|
Peripheral oxygen saturation (SpO₂) is measured using wearable physiological sensors as an indicator of oxygenation status during therapy.
|
Immediately before and immediately after Session 1 (Baseline), and immediately before and immediately after Session 36 (Week 12)
|
|
Change in salivary cortisol concentration
Tidsramme: Immediately before and immediately after Session 1 (Baseline), and immediately before and immediately after Session 36 (Week 12)
|
Salivary cortisol concentration is measured as a physiological biomarker of stress and hypothalamic-pituitary-adrenal (HPA) axis activity.
|
Immediately before and immediately after Session 1 (Baseline), and immediately before and immediately after Session 36 (Week 12)
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Afvigende motorisk adfærd ved demens
- Neurologiske manifestationer
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Psykiske lidelser
- Adfærdsmæssige symptomer
- Neuroadfærdsmæssige manifestationer
- Neurokognitive lidelser
- Kognitionsforstyrrelser
- Dyskinesier
- Psykomotoriske lidelser
- Patologiske tilstande, tegn og symptomer
- Tegn og symptomer
- Kognitiv dysfunktion
- Depression
- Demens
- Psykomotorisk agitation
- Opførsel
- Sundhedstjenester Administration
- Sundhedsvæsenets kvalitet, adgang og evaluering
- Terapeutik
- Sundhedskvalitet
- Kvalitetsindikatorer, sundhedsvæsenet
- Patientpleje
- Sundhedstjenester
- Sundhedsfaciliteter Arbejdsstyrke og tjenester
- Rehabilitering
- Efterpleje
- Kontinuitet i patientpleje
- Neurologisk rehabilitering
- Standard for pleje
- Kognitiv træning
- Ergoterapi
Andre undersøgelses-id-numre
- UPrimosrka
- 0120-104/2020/6 (Anden identifikator: Slovenian National Medical Ethics Committee)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Demens
-
ACADIA Pharmaceuticals Inc.RekrutteringLewy Body Dementia PsychosisForenede Stater, Tjekkiet, Serbien, Frankrig, Bulgarien, Italien
-
ACADIA Pharmaceuticals Inc.Tilmelding efter invitationLewy Body Dementia PsychosisForenede Stater, Tjekkiet, Bulgarien
Kliniske forsøg med Snoezelen Multisensory Therapy
-
Muş Alparslan UniversityRekruttering
-
Bahçeşehir UniversityAfsluttetAngst | SmertebehandlingKalkun
-
Centre Hospitalier Universitaire de NīmesAfsluttetSansestøtte til ældre patienter, der lider af neurodegenerativ sygdom af Alzheimers type (SensiCare)Alzheimers sygdomFrankrig
-
State University of New York at BuffaloAfsluttet
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Aktiv, ikke rekrutterende
-
University of PennsylvaniaAfsluttetTilbagevendende Clostridium Difficile-infektionForenede Stater
-
Douglas MenninWeill Medical College of Cornell University; Kent State UniversityAfsluttetGeneraliseret angstlidelse | Depression, angst | Angstlidelser og symptomer | Følelsesmæssig dysfunktionForenede Stater
-
Foundation University IslamabadRekrutteringCerebral parese (CP) | Fysisk funktionel ydeevnePakistan
-
National University Hospital, SingaporeNational University, Singapore; Agency for Science, Technology and ResearchAfsluttet
-
Tata Memorial CentreRekrutteringOndartet neoplasma i analkanalenIndien